<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219516</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-108</org_study_id>
    <nct_id>NCT02219516</nct_id>
  </id_info>
  <brief_title>Mild, Moderate and Severe Renal Impairment Study</brief_title>
  <official_title>A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD)
      study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of RDEA3170 from plasma and urine</measure>
    <time_frame>Plasma measured Day 1: within 30 minutes prior to dosing and at 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 30, 36, 48, 54, 60, and 72 hours postdose</time_frame>
    <description>PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); apparent terminal half-life (t1/2); Non-renal clearance (CLNR); renal clearance (CLR); and total body clearance corrected for bioavailability (CL/F)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD profile of RDEA3170 from serum and urine PD profile of RDEA3170 from serum and urine</measure>
    <time_frame>Screening, Day -1 ( -24, -21, -18, -and -12 hours predose), and Day 1 (within 30 minutes prior to dosing and at 3, 6, 12, 24, 30, 36, 48, 54, 60, and 72 hours postdose)</time_frame>
    <description>PD endpoints in terms of serum urate concentration, urine uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 15 mg once daily fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 15 mg once daily fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 15 mg once daily fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Control subjects with normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 15 mg once daily fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170</intervention_name>
    <arm_group_label>Cohort 1: Mild renal impairment</arm_group_label>
    <arm_group_label>Cohort 2: Moderate renal impairment</arm_group_label>
    <arm_group_label>Cohort 3: Severe renal impairment</arm_group_label>
    <arm_group_label>Cohort 4: Control subjects with normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40
             kg/m2.

          -  Subject with renal impairment, as determined at Screening, with creatinine clearance
             as calculated by the Cockcroft-Gault formula of 60 to &lt; 90 mL/min (mild impairment),
             30 to &lt; 60 mL/min (moderate impairment), or 15 to &lt; 30 mL/min (severe impairment), or
             a matched control subject (by age and body mass index) with a creatinine clearance of
             ≥ 90 mL/min.

          -  Subject has a Screening serum urate level ≥ 4.5 mg/dL and ≤ 10 mg/dL

        Exclusion Criteria:

          -  Subject has a history or clinical manifestations of significant metabolic,
             hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic,
             renal, urological, or psychiatric disorders.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has a history of asthma.

          -  Subject has undergone major surgery within 3 months prior to Day 1.

          -  Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12
             weeks prior to Day 1 or gave a plasma donation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>August 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
